A simplified disease activity index for rheumatoid arthritis for use in clinical practice
Top Cited Papers
Open Access
- 1 February 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (2) , 244-257
- https://doi.org/10.1093/rheumatology/keg072
Abstract
Objective. The objective of this study was to verify the usefulness of a simple disease activity index (SDAI) for rheumatoid arthritis (RA). Methods. The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28‐joint assessment), patient and physician global assessment of disease activity [visual analogue scale (VAS) 0–10 cm] and level of C‐reactive protein (mg/dl, normal Results. The mean SDAI calculated for patients at baseline in study MN301 was 50.06 (range 25.10–96.10) and was, respectively, 50.55 (range 22.10–98.10) and 43.20 (range 12.90–78.20) in studies MN302 and US301. In all three trials, the SDAI was correlated with a high level of statistical significance to the DAS 28 and HAQ scores at baseline, endpoint and change at endpoint. Patients achieving the ACR 20, 50, 70 or 90% response showed proportionate changes in the SDAI. Analysis of surveyed physician responses showed a significant association between the perception of disease activity and the SDAI, as well as changes in the SDAI. Qualitative analysis of radiographic progression at 6 and 12 months for patients showing either major, minor or no improvement of the SDAI showed correspondingly larger increases of the total Sharp score at 12 months. Conclusion. The SDAI is a valid and sensitive assessment of disease activity and treatment response that is comparable with the DAS 28 and ACR response criteria; it is easy to calculate and therefore a viable tool for day‐to‐day clinical assessment of RA treatment. Overall results indicate that the SDAI has content, criterion and construct validity.Keywords
This publication has 25 references indexed in Scilit:
- Progress Towards Optimal Trial End-Points in Rheumatoid ArthritisBioDrugs, 1997
- Development and Validation of Response Criteria in Rheumatoid Arthritis: Steps Towards an International Consensus on Prognostic MarkersRheumatology, 1996
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activityArthritis & Rheumatism, 1995
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placeboArthritis & Rheumatism, 1990
- Which traditional measures should be used in rheumatoid arthritis clinical trials?Arthritis & Rheumatism, 1989
- A simplified twenty‐eight–joint quantitative articular index in rheumatoid arthritisArthritis & Rheumatism, 1989
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988